Under- and overweight generics drive recalls

Weight problems are driving recalls of generic products. In recent Teva recalls, both metronidazole tablets and gabapentin capsules are underweight, while overweight tablets have saddled Caraco, Ethex and Actavis Totowa with recall actions over the past two years.

For Teva, the one-lot metronidazole callback affects sufferers of the STD trichomoniasis in the U.S. The four-batch recall of seizure treatment gabapentin affects the U.K.

The Activis 2008 recall involved the heart drug Digitek (digoxin) for pills that could contain twice the approved level of API. Caraco also recalled digoxin. An Ethex recall involved oversized morphine tablets, reports AboutLawsuits.com.

The Teva metronidazole lot is packaged in 250 count bottles and was distributed nationwide to wholesalers and retailers, who were notified of the recall in late October. Gabapentin underwent a class 2 recall, requiring action within 48 hours and quarantining of the product, in late December.

- see the story
- here's the metronidazole recall notice
- and the gabapentin notice

Suggested Articles

Fujifilm Diosynth Biotechnologies last year committed 10 billion yen toward its manufacturing operations. It has now kicked off one of those projects.

Popular logic says you never switch horses, or CDMOs, in the middle of the stream, but Acacia Pharma had to do that to win an FDA approval.

The FDA has found issues with the testing practices of a U.S. generics maker that had specific problems with ADHD and weight-loss drugs.